1. PLoS Med. 2005 Mar;2(3):e75. doi: 10.1371/journal.pmed.0020075. Epub 2005 Feb 
22.

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its 
ugly head.

Clark J(1), Cools J, Gilliland DG.

Author information:
(1)Harvard Medical School, Brigham and Women's Hospital, and the Dana-Farber 
Cancer Institute, Boston, Massachusetts, USA.

Comment on
    PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073.

Most patients with non-small cell lung cancer who initially respond to gefitinib 
or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and 
disease relapse. What is the mechanism for this resistance?

DOI: 10.1371/journal.pmed.0020075
PMCID: PMC549608
PMID: 15736989 [Indexed for MEDLINE]

Conflict of interest statement: Competing Interests: The authors declare that 
they have no competing interests.